Omeprazole/sodium bicarbonate capsule - Salix Pharmaceuticals

Drug Profile

Omeprazole/sodium bicarbonate capsule - Salix Pharmaceuticals

Alternative Names: Omeprazole/sodium bicarbonate OTC; SAN 15; Zegerid Capsules; Zegerid Chewable Tablets; Zegerid OTC

Latest Information Update: 07 Apr 2015

Price : $50

At a glance

  • Originator Santarus
  • Developer Norgine; Salix Pharmaceuticals; Santarus
  • Class Antiulcers; Gastric antisecretories
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Erosive oesophagitis; Gastro-oesophageal reflux; Heartburn; Peptic ulcer

Most Recent Events

  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals
  • 01 Feb 2011 Norgine completes a Phase-I trial in Erosive oesophagitis, Gastro-oesophageal reflux and Peptic ulcer (in volunteers) in United Kingdom (NCT01710995)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top